SINGAPORE, May 24, 2018 /PRNewswire/ — BETADINE®, which is produced by multinational healthcare organisation Mundipharma, is the first ever consumer healthcare brand to launch a web-based chat bot for feminine care.
Equipped with a combination of Machine Learning and Natural Language Processing capabilities to interact with people, and simultaneously self-train over time, the chat bot provides a private way for women to ask questions and learn about the importance of feminine care.
It can also provide information about the uniquely comprehensive range of daily-use BETADINE® Feminine Care products, help people request samples, link to e-commerce sites and geo-direct people to nearby retail stockists. The chat bot has affectionately been named ‘Betty’.
A pilot launch in Singapore has shown impressive results, including a 194% increase in average website session duration on myfemcare.com where Betty is currently hosted. It will soon be launched in other countries around the world and programmed to respond in other languages.
Mundipharma CEO, Raman Singh, said “Not everyone is comfortable talking about this topic so we wanted to create another way for women to seek advice.“
“We’re proud to have developed this ground-breaking chat bot, which I believe provides a glimpse into the future of healthcare — one which, facilitated by technology, provides people with options and convenience, and empowers them to make informed decisions that best suit their healthcare needs.“
“This is the latest in a series of digital initiatives we’ve rolled out as we aim to make this future a reality and continue to harness the power of technology to improve healthcare outcomes for all.”
The BETADINE® range of products has been trusted around the world for over 60 years to prevent and treat infections, and provide daily care. It is a trusted brand among consumers at home to treat small wounds and grazes and sore throats, and for daily hygiene. This stops minor problems from escalating into big issues. In-vitro studies show that BETADINE® medicines that contain Povidone-Iodine kill a broad range of bacteria, viruses and fungi that cause infections, including antibiotic-resistant strains. BETADINE® has four main categories of products in Wound Care, Throat / Oral Care and Feminine Care.
®: BETADINE is a registered trademark of Mundipharma
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
SINGAPORE, May 28, 2018 /PRNewswire/ — Mundipharma CEO, Raman Singh, has been included in the 2nd Edition of Asia’s Greatest Leaders, which is published by AsiaOne and chosen by consumers and industry in a selection process reviewed by PricewaterhouseCoopers.
Mundipharma CEO Raman Singh Named One of Asia’s Greatest Leaders
This follows an awards ceremony held at the Marina Bay Sands, Singaporein January, which was attended by top CEO’s, investors, ambassadors, dignitaries, celebrities, and business icons amongst others.
The purpose of this prestigious publication is to celebrate the emergence of Asia as the fastest growing economy. Asia’s Greatest Leaders is a platform for recognising leadership excellence in the region.
Mr Singh, who was recently chosen to be a Business Brand Ambassador for the Singapore Tourism Board, joins fellow iconic leaders featured in book such as Alibaba’s Jack Ma, Temasek’s Madam Ho Ching and Facebook Co-Founder Eduardo Saverin.
This latest accolade follows recent recognition as Medicine Maker’s top Asian executive, and number three overall, in 2018 — the fourth year in succession that Mr Singh has featured among the publications’ top 10 business leaders. He was also named among the Top 100 Global CEOs by CEO Magazine in a ceremony in London this year. In addition, Mundipharma’s efforts in healthcare innovation were recently acknowledged by winning a Stevie Award this year.
Acknowledging the latest accolade, Mr Singh said, “I am humbled to be included among other Asian leaders and pioneers in this region, which is increasingly becoming the world’s growth engine, but where there are still many healthcare challenges to tackle.
“Success in business requires building high-performing ambitious teams and I’m privileged to lead a fantastic group of people. It’s nice to be recognized in so many ways, but ultimately the motivation for everybody at Mundipharma — the number-one value underpinning our culture — is putting people and patients at the heart of everything we do. This award reflects the culture we’ve created and the people who embody it.”
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
— Telemedicine Pilot Project with Russian Railways & SNU Bundang Hospital –
— Expansion of ICT-based Medical Treatment by the Health-Welfare Ministry –
SEOUL, South Korea, May 24, 2018 /PRNewswire/ — KT Corp. (KRX: 03200; NYSE: KT) announced today that it will install a telemedicine system on the trans-Siberian railway and facilitate digital healthcare solutions by connecting hospitals affiliated with the state-owned Russian Railways.
The pilot plan is part of the ICT-based Medical System Expansion Project spearheaded by the Korea Health Industry Development Institute, an agency of the Ministry of Health and Welfare. KT, South Korea’s leading telephone and Internet provider, also participated in the project in 2017, constructing a digital healthcare platform and solution for 12 hospitals in Kazakhstan.
KT and Russian Railways signed an agreement in December 2017 to jointly create a mobile diagnostics solution for primary care at hospitals in Russian rail stations as well as on trans-Siberian trains. Russian Railways, one of the world’s three largest rail transportation companies, manages 173 hospitals across Russia.
Under the agreement, KT will work with the Seoul National University Bundang Hospital to set up a telemedicine system for six hospitals, one in Moscow and five in various regions, by June. KT will supply a digital healthcare solution, and the SNU hospital will offer diagnostic advice to Korean and Russian medical staffs and assist in personnel training. The telemedicine system for trans-Siberian trains will be maintained until the end of this year.
Koh Yoon-Jeon, Chief of KT’s Future Business Development Unit, she expects that KT will successfully undertake the project with its outstanding capabilities accumulated in digital healthcare over the years.
“We further look forward to expand our endeavors in Russia, particularly in the fields of online medical care, healthcare platform, and ICT-based operations of diagnosis centers and convalescent homes,” Koh said. “To this end, we are advancing our expertise in big data analysis and artificial intelligence (AI) technology, and also accelerating our efforts to achieve cooperation in e-healthcare with local partners, including the state-owned Sberbank.”
Jheon Sang-Hoon, President of the Seoul National University Bundang Hospital, said, “The convergence of healthcare and information technology is a major trend these days, and our hospital has been making diverse efforts in this field to make our way into the global market. This will be a good opportunity to introduce Korea’s prowess in ICT in medicine.”
KT’s Digital Healthcare Solution and Platform won the Award for Best Mobile Innovation for Health at the Mobile World Congress 2018, held in February, in Barcelona, Spain
The trans-Siberian railway, operated by Russian Railways, connects Moscow and Vladivostok. A one-way trip takes seven days. Currently, the trans-Siberian trains only have basic diagnostic devices such as thermometers and blood pressure monitors. Therefore, it is difficult to check the condition of passengers who should be monitored closely such as pregnant women and heart patients or realize a passenger has an internal organ problem that requires urgent treatment.
KT plans to install its digital healthcare solution devices on the trains. They will enable rapid diagnosis with a small amount of blood and urine on such cardiovascular diseases as angina and myocardial infarction, as well as respiratory diseases, diabetes and prostate cancer. The solution also provides ultrasonography to diagnose kidneys, liver and gallbladder, fetal sonography, and basic blood and musculoskeletal system tests.
Notably, KT’s digital healthcare platform features mobile diagnostics software containing Bluetooth and Wi-Fi for management of diagnostic data and storage of patients’ medical history in the “mobile electronic medical record (Mobile EMR).” It also utilizes AI technology for precise and accurate diagnosis, as exhibited by chest X-ray interpretation based on machine learning.
Media Contacts
For inquiries, please contact our Foreign Media Relations Team at kt.fmrt@gmail.com
About KT Corp. (KRX: 030200, NYSE: KT)
KT Corporation, Korea’s largest telecommunications service provider reestablished in 1981 under the Telecommunications Business Act, is leading the era of innovations in the world’s most connected country. The company leads the 4th industrial revolution with high speed wire/wireless network and innovative ICT technology. After installing 4.5 million fixed lines for 20 million users in just 12 years, KT was the first telecom provider to introduce 5G broad-scale trial service in 2018. It is another step in KT’s continuous efforts to deliver essential products and services as it seeks to be the No.1 ICT Company and People’s Company.
Treatment of agitation in the elderly in hospital and nursing home settings represents a rapid potential path to market for BNC210
No currently approved treatments and significant unmet medical need
Trial designed for rapid recruitment with results anticipated first quarter calendar year 2019; first patient recruited
PTSD clinical trial on track; data anticipated second half calendar year 2018
MELBOURNE, Australia, May 24, 2018 /PRNewswire/ — Bionomics Limited (ASX:BNO) (OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, today announces that a Phase 2 clinical trial of its therapeutic candidate, BNC210, has commenced in elderly patients with agitation in the hospital setting. The first participant has been recruited into the trial.
Agitated behavioural disturbance in elderly patients is a major unmet clinical problem, occurring acutely in hospitalised patients and chronically in nursing home residents. These agitated behaviours can cause distress for the patient, distress to other patients, and can interfere with the therapeutic procedures for which the patient was hospitalised. Whilst there are no approved treatments for agitation, current options include benzodiazepines and antipsychotics which can have severe adverse effects in elderly patients including sedation, stroke and sudden death, and hence their use is heavily restricted.
The trial, designed for short treatment and rapid recruitment, will evaluate the effect of BNC210 on the resolution of agitation in hospitalised elderly patients and assess the safety and tolerability of BNC210 in this patient population. It will recruit approximately 40 elderly patients in specialist geriatric hospital wards across Australiaand is a randomised, double-blind, placebo-controlled design with a 5-day treatment period.
Results of this clinical trial will be available in Q1, CY2019.
Dr Deborah Rathjen CEO & Managing Director commented, “Bionomics has entered an important period with the results of two ongoing Phase 2 trials now anticipated near term. Agitation in the elderly, which has an underlying component of anxiety, has significant unmet treatment needs, with only approximately 9% of patients suffering agitation receiving drug treatment1“.
“The hospitalised or nursing home agitation setting represents a rapid potential path to market for BNC210 and builds on the findings of the successful Phase 2 clinical trial of BNC210 in patients with Generalised Anxiety Disorder (GAD)”
“Last month we completed recruitment into our BNC210 Phase 2 clinical trial in patients suffering Post-Traumatic Stress Disorder (PTSD). As previously advised we anticipate data in 2H, CY2018,” Dr Rathjen added.
BNC210 is a novel, first-in-class, negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. It has been shown to be well tolerated and not sedating. Furthermore, clinical trials have shown effects of BNC210 that are consistent with anti-anxiety action, even after a single administration, indicating a rapid onset of action and potential for therapeutic benefit in agitated elderly patients. Agitation in elderly patients has an underlying component of anxiety.
1 National Institutes for Mental Health, Cowen Therapeutic Categories Outlook March 2016
FOR FURTHER INFORMATION PLEASE CONTACT:
Australia US Monsoon CommunicationsStern Investor Relations Rudi MichelsonBeth DelGiacco +613 9620 3333 +1 212 362 1200 rudim@monsoon.com.aubeth@sternir.com
About Bionomics Limited
Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in Phase 2 for the treatment of generalised anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).
BNC210 is a novel small molecule, orally-administered drug candidate being developed for anxiety and trauma- and stressor-related disorders, that we believe has similar efficacy but improved tolerability compared to currently available drugs such as benzodiazepines, selective serotonin reuptake inhibitors, or SSRIs, and serotonin-norepinephrine reuptake inhibitors, or SNRIs. BNC210 is a first-in-class highly-selective negative allosteric modulator of the alpha-7 nicotinic acetylcholine (alpha-7) receptor. Acetylcholine and the alpha-7 receptor are increasingly being implicated in the symptoms of anxiety and depression. Furthermore, the alpha-7 receptor is highly expressed in the amygdala, which forms part of the emotional centre of the brain. To date, BNC210 has been evaluated in seven completed clinical trials in over 200 subjects. Recruitment has just been completed in a Phase 2 Post-Traumatic Stress Disorder trial with 193 participants.
Factors Affecting Future Performance
This announcement contains “forward-looking” statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ drug candidates (including BNC210, BNC101 and BNC105), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors’ drugs and drug candidates may vary from those reported when tested in different settings.
Clinical Appendix
Study Title:
A Phase II Randomised, Double-blind, Placebo-controlled Pilot Study to Assess the Efficacy and Safety of BNC210 in Hospitalised Elderly Patients with Agitation
Study Number:
BNC210.008
Clinical Phase:
Phase 2
Study Design:
Randomised, double-blind, parallel-dosing of BNC210 and placebo in a 1:1 ratio
5 days of treatment, with a 2 day follow up period
Approximately 40 hospitalised elderly patients with agitation in specialist geriatric hospital wards across Australia
Primary Objective:
To compare the effect of BNC210 and placebo on the time course of resolution of agitation in hospitalised elderly patients as measured by the Pittsburgh Agitation Scale (PAS).
Secondary Objectives:
To compare the effect of BNC210 and placebo on the time course of change in global function in hospitalised elderly patients as assessed by the Clinical Global Impression Scale – Severity and Improvement (CGI-S/I).
To assess safety and tolerability of BNC210 in hospitalised elderly patients with agitation.
Exploratory Objective:
To obtain preliminary estimates of pharmacokinetics of BNC210 in elderly patients.
SHANGHAI, May 24, 2018 /PRNewswire/ — Pivotal bioVenture Partners China (Pivotal China), a member of Nan Fung Life Sciences (NLFS) announced today the closing of Pivotal bioVenture Partners China USD Fund I, raising $150 million to incubate and build Life Sciences companies in China. Pivotal China was founded by Mr. Vincent Cheung, who is the Chairman of NFLS and Managing Director and COO of Nan Fung Group. It is led by Dr. Jimmy Wei, Mr. Meng Gao and Mr. Shannon Cheung. Pivotal China will focus on incubating new life sciences companies in China by in-licensing innovative products and technologies that could serve unmet medical needs of the growing China market. Pivotal China will invest broadly in pharmaceuticals, devices and service sectors.
“China is catching up in healthcare innovation,” said Dr. Jimmy Wei, Managing Partner of Pivotal bioVenture Partners China. “By creating new companies with entrepreneurs and global partners, Pivotal China fund intends to bring global technologies to China quickly and efficiently. The vision of Pivotal China is to create a life sciences ecosystem to generate synergies among portfolio companies and foster the innovations in China. We are doing this by building one of the most experienced teams among our peers, and by combining a broad global exposure with strong expertise in the local Chinese market. Leveraging on Nan Fung Life Sciences’ presence in the US and Europe, we hope to actively source cutting-edge innovative technologies.”
Prior to joining Pivotal China, Dr. Jimmy Wei was the Managing Partner at iBridge Capital and the Partner at the KPCB China fund, where he was involved with the formation of companies such as Zai Lab, JHL Biotech, XW Lab and iMab. Prior to joining Pivotal China, Mr. Meng Gao was a Managing Director at Blackstone’s Private Equity Group and Mr. Shannon Cheung was the Founder and Chief Executive Officer of Averest Capital, an investment company focusing on healthcare, TMT and environmental technology sectors and Co-Founder and Vice Chairman of Likang Life Sciences.
About Nan Fung Life Sciences (NFLS)
Nan Fung Life Sciences, part of Nan Fung Group, is a global investment platform focusing on life sciences. Leveraging on Nan Fung Group’s strong capital base and long-term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations and investors in the life science space. Through direct investments via Pivotal bioVenture Partners funds (both in US and China) and fund investments covering full spectrum of the industry (including therapeutics, medical devices and diagnostics) and across different development stages, Nan Fung Life Sciences has significant presence in both US and Greater China.
About Nan Fung Group
Nan Fung Group, founded in 1954, Nan Fung Group is a conglomerate based in Hong Kong with global interests in real estate development and investment, life sciences and financial investments. Learn more at www.nanfung.com/.
LUGANO, Switzerland, May 24, 2018 /PRNewswire/ — At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda.
ESMO advocated the strengthening of health systems to achieve Universal Health Coverage and to provide essential secondary healthcare services to the millions of cancer patients who die prematurely due to lack of access to appropriate treatment.
The widespread availability of secondary healthcare services to cancer patients depends on the presence of sufficient numbers of well-trained oncology professionals with sustainable access to the resources required to perform surgery, deliver radiotherapy, administer cancer treatments, provide supportive and palliative care. ESMO is active in many of these areas and able to support individual Member States’ efforts.
Alexandru Eniu, ESMO Global Policy Committee Chair: “ESMO has worked with the WHO for over 15 years to improve cancer care worldwide. The platform we were given to talk about cancer illustrates how prominent the topic is becoming on the global health agenda and confirms the relevance of our continued collaboration.”
ESMO President Josep Tabernero: “It was a privilege for us to be able to speak directly to the international community about the pressing global health issue that is cancer. ESMO is ready to support the WHO and Member States in strengthening the medical oncology workforce and in identifying the most cost-effective interventions and treatments that can immediately help reduce the number of cancer deaths worldwide.”
ESMO is the leading professional organisation for medical oncology. With 18,000 members representing oncology professionals from 150 countries worldwide, ESMO is the society of reference for oncology education and information.
-Drug Substance produced in AGC Biologics’ facility in Bothell, Washington
BOTHELL, Washington, May 24, 2018 /PRNewswire/ — AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that it will supply bulk drug substance for the launch of Portola Pharmaceuticals’ Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Andexxa® received both U.S. Orphan Drug and FDA Breakthrough Therapy designations, and was recently approved under the FDA’s Accelerated Approval pathway based on the change from baseline in anti-Factor Xa activity in healthy volunteers. Continued approval for this indication may be contingent upon post-marketing study results to demonstrate an improvement in hemostasis in patients.
AGC Biologics is presently manufacturing bulk drug substance for Portola’s planned launch of Andexxa®.
“We are extremely pleased to have had the opportunity to help Portola provide this unique antidote for rivaroxaban- and apixaban-treated patients with life threatening or uncontrolled bleeding,” said Gustavo Mahler, Ph.D., President & Chief Executive Officer of AGC Biologics. “Our facilities in the United States, Denmark and Japan enable us to provide unique and robust manufacturing solutions to bring products to market globally. As with Portola, our commitment to deliver marketed products is prioritized across our entire organization.”
About AGC Biologics
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a strong commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics. The company currently employs more than 850 employees worldwide. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Berkeley, CA; Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan.
AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics; from pre-clinical to commercial production, for mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression — including our proprietary CHEF1® Expression System for mammalian production. Further information can be found at www.agcbio.com.
AGC Biologics Media Contact Information: Ms. Kim Yang Director, Global Marketing and Communications Email: kyang@agcbio.com Office: +1 425.415.5438
BEIJING, May 25, 2018 /PRNewswire/ — Co-hosted by the China Association of Chinese Medicine (CACM), People’s Daily Online and Health.People.cn, and organized by Infinitus (China) Company Ltd. (Infinitus (China)), a member of LKK Health Products Group, the 2018 Responsibilities for Health Forum and the launch conference of the China’s National Traditional Chinese Medicine (TCM)Health Index Report 2017 (the report) took place in Beijing on May 23, 2018. On the basis of Healthy China Initiative, the forum discussed the responsibilities for health and roles of the government, associations, experts, media and enterprises.
The China’s National TCM Health Index Report 2017 was jointly released by Infinitus (China) and CACM
The distinguished guests attending the event included Mr. Li Daning, former deputy director of the State Administration of Traditional Chinese Medicine of the P.R.C, Mr. Liu Ping, deputy secretary general of CACM, Mr. Guan Zhusun, executive dean of Golden Bee Corporate Social Responsibility (CSR) Research Institute of Huazhong University of Science and Technology, and Mr. Huang Jianlong, senior vice president of Infinitus (China).
Responsibilities for health promote the Healthy China
The national health should be regarded as a strategic priority, Mr. Li Daning emphasized on the forum. He said, the health industry in the future will cover various realms such as life sciences, TCM nourishing knowledge, psychology and sociology, as well as some emerging industries such as Internet of Things and cloud platforms. It will boost many new interdisciplinary, cross-domain or cross-industry businesses. The health industry definitely owns a broad and bright future.
As a company focusing on R&D, production, sales and services of Chinese herbal health products, Infinitus (China) has forged the corporate mission of “advocating the premium Chinese health regimen and nurturing healthier lives with balance, affluence and harmony” since its foundation, introduced by Mr. Huang Jianlong.
Infinitus renews the philosophies to power the practices of social responsibilities
Mr. Liu Ping and Mr. Huang Jianlong jointly signed and issued the report on the spot. Viewing four aspects of emotion, diet, exercise and rest with an angle of TCM, the report analyses the health status of Chinese people and the factors influencing it. The report also offers practical advices that could be applied in daily life, allowing readers to clearly understand and consciously improve their health level.
According to the report, the China’s national TCM health index 2017 is 64.6, a notably increase compared to 2016, but the room for improvement still exists for the half of the population suffering from diverse diseases or in the semi-health state.
“If we say the theory of TCM belongs to the wisdom of the East, and the measure of indexing belongs to methodologies of the West, then the China’s national TCM health index announced today is a combination of the two in a way that they complete each other, and create new value.” illustrated by Mr. Huang Jianlong.
Regarding the responsibilities for health, Infinitus reckons the enterprises should broaden their thinking, make use of their own advantages and resources, leverage innovation ideas, patterns and practices to spur the development and upgrade of the whole health industrial chain.
On the forum, Mr. Guan Zhusun, executive dean of Golden Bee CSR Research Institute of Huazhong University of Science and Technology, said, Infinitus has become a model for Chinese enterprises on account of some of its practices like incorporating social responsibilities into its strategic development and releasing CSR reports for 11 consecutive years.
-Lecture by Dr. Yim, Joonghyuk, Director of TL Plastic Surgery of Korea
SEOUL, South Korea, May 24, 2018 /PRNewswire/ — Dr. Yim, Joonghyuk, Director of TL Plastic Surgery of Korea, was invited as a lecturer in the Industrial Session of APS 2018, an international symposium of the Korean Society of Aesthetic Plastic Surgery and the Korean Association of Plastic Surgeons held in Grand Ballroom of COEX from Apr. 7th to Apr. 8th.
Dr. Yim, Joonghyuk, Director of TL Plastic Surgery of Korea spoke at the Industrial Session of APS 2018
Dr. Yim, Joonghyuk, a specialist at TL Plastic Surgery who has been invited to countless conferences at home and abroad for lectures on the analytic data on all prosthetics launched in Korea with his outstanding morphological analysis of prosthetics through his prolonged career and extensive range of experiences, presented the characteristics of and surgical know-how for Bella Gel Micro at APS 2018.
Dr. Yim, Joonghyuk stated in his presentation that, “Selecting the size that harmonizes with your body is the fundamental consideration to be made and it is important to accurately assess the problems of the breast to solve them simultaneously. The surgical method that is most appropriate for you after having meticulously diagnosed your daily life pattern, bust size, shape of thorax and configuration of the chest, etc. is recommended.”
In particular, the “Majority of patients have asymmetry of the body that they are not aware of and, as such, it is essential to select surgical approaches and size and type of prosthetics most appropriate for the patient in accordance with the accurate analysis. Although new prosthetics, including Motiva or Bella Gel, are receiving a lot of attention recently, prosthetics that are most suitable for the patient, rather than those known to have extensive range of advantages, are the best prosthetics.”
In addition, the scar along the incision line is one of the issues that patients are most concerned about. Incisions can be made in the armpit, below the breast and mammary areola with each area having their respective advantages and disadvantages. Among these, the incision in the armpit is most preferred by the majority of patients due to the advantage of less conspicuous signs of surgery since incision line can be hidden. High-resolution endoscopic equipment is used for surgery involving incision in the armpit due to the difficulty in securing a clear view from the incision line to the location of insertion of prosthetics. It is normally recommended that highly capable specialists with an extensive range of surgical experiences perform the procedure due to the difficulties in securing the view to create the space needed and precisely deal with the key blood vessels while performing hemostasis at the same time. Although incisions via the armpit has the advantage of a less conspicuous scar, the recovery period is longer and there may be more restrictions in the use of arm in comparison to other areas. Accordingly, it is advisable to decide the incision area through consultation with a specialist. Moreover, patients are recommended to use laser and scar ointments after the surgery regardless of the incision area selected.
TL Plastic Surgery of Korea was established in 2008 in Seoul and is currently situated in Gangnam region. Dedicated specialists with abundance of clinical experiences in each of their areas of specialization are providing differentiated medial services by personally executing medical examinations and ensuing surgical procedures. TL Plastic Surgery of Korea not only has dedicated anesthetic system since mammoplasty is performed under general anesthesia, but also dedicated mammoplasty system for execution of surgical procedures with foremost priority on the safety of the patient.
Dr. Yim, Joonghyuk, a specialist in mammoplasty at TL Plastic Surgery of Korea, is a medical doctor with specialization in plastic surgery with more than 20 years of experience. He has been providing lectures on mammoplasty for sagging breast or re-surgery of breast by using prosthetics such as tear-drop and Motiva, to other medical staff not only in Korea but in other countries. Furthermore, he is helping to expose the excellence of plastic surgery procedures in Korea to other parts of the world by sharing and demonstrating various live mammoplasty techniques designed to enhance stability and accuracy by using HD endoscopic equipment.
TL PLASTIC SURGERY KOREA
Honey Lee Mobile / Whatsapp: +82-10-7667-7197 Kakao / Line / WeChat: tlpsbody Facebook: facebook.com/tlpsbody E-mail: tlbreast@gmail.com
– 3rd approval for Plant 2 in just 26 months since GMP ready – CEO TH Kim “Samsung BioLogics once again demonstrated its superior quality capability with data integrity”
INCHEON, South Korea, May 24, 2018 /PRNewswire/ — Samsung BioLogics announced today that a third monoclonal antibody Drug Substance has been licensed by the US FDA (Food and Drug Administration) for its second plant, the world’s largest single plant.
With the approval, Samsung BioLogics has been approved by the FDA for the manufacture of three commercial Biologics Drug Substances at only its second plant in just 26 months since being GMP ready in 2016.
Samsung BioLogics has improved production efficiency through the installation of ten 15,000L bioreactors, a world’s first, breaking industry stereotypes to install and operate only four or six bioreactors in a single bio-manufacturing plant.
Samsung BioLogics has demonstrated that both Plant 1 and Plant 2 are compliant with global GMP standards through receiving 14 global regulatory agency’s approvals including FDA, EMA, and PMDA.
Although Plant 2 is 5 times larger and 10 times more complicated, Samsung BioLogics received initial manufacturing approval 6 months faster than Plant 1. This shortened time in construction and period of approval allows our clients to quickly supply their products to the market.
With its competitiveness, Samsung BioLogics has won the CMO Leadership Award presented by Life Science Leader in all six core categories for two consecutive years.
For the 2018 CMO Leadership Awards, more than 110 CMOs from around the world were evaluated on 23 performance metrics to determine winners in the six categories. Only CMO clients participate in the survey, which enhances the validity of the award.
TH Kim, CEO and President of Samsung BioLogics, said “There has been some cases recently where CMO’s failure of receiving approval affects the clients’ drug marketing schedule.” Then he added that “Samsung BioLogics has once again demonstrated that it possesses world class Quality with Data Integrity which is critical to get global approvals. Samsung BioLogics has been striving to establish a system to completely prevent even tiny data errors that may occur during the whole production process of biopharmaceuticals from the establishment of the company and to set it up as a corporate culture.
TH Kim also said “We will continue to do our best to continuously innovate ourselves so that clients and patients can receive high quality medical products in a timely manner”
Samsung BioLogics will be attending the BIO International 2018 Conference in BostonJune 4-7, 2018, as an exhibitor for the 8th year in a row to pursue additional contracts.
